"March 15, 2015(CNN) — ....Eleven Americans are being flown back to the United States.... Four people who had “more exposure than the others” to the patient with Ebola will isolate themselves in housing on the campus of the University of Nebraska Medical Center, said Nebraska Medicine spokesman Taylor Wilson. They arrived on the medical campus Saturday evening, Wilson said."
If you recall on November 17th the University of Nebraska Medical Center was the hospital that seemed prepared to use Athelon's hemopurifier on Dr. Martin Salis the last infected US national, but unfortunately he died before the paper work could be completed. After his death the FDA removed this paper work hurdle for Aethlon's hemopurifier with an "emergency use" designation.
"In the United States, Hemopurifier® therapy is available to treat Ebola patients through FDA expanded access "emergency use" provisions to address life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans. Aethlon disclosed that it provided Hemopurifiers to the NMC on a humanitarian basis...."
At the time of Dr. Salis admittance on Nov 15, 2015 two days before his death the hemopurifier hadn't received the "emergency use" designation it could only provide Hemopurifier® therapy on a humanitarian basis through FDA compassionate use access provisions, which allow for the use of an investigational device to treat an individual patient or small group based on clearance by FDA prior to treatment. It was this extra time needed to receive clearance that perhaps cost Dr. Salis his life.
All those that have researched Aethlon's hemopurifier and the other treatment candidates know his best certainty for survival and others infected with Ebola is thru the hemopurifier. It has the proven ability to remove viruses from the bloodstream and has proven numerous times to save peoples lives, once with Ebola (Dr. Michael Mawanda) and countless times with other viruses.
To date, Hemopurifier therapy has been successfully administered in approximately one hundred treatment experiences in health compromised HIV and HCV infected individuals. In vitro validation studies that demonstrated the ability of the Hemopurifier to capture Zaire and other strains of ebola virus were conducted by researchers at the United States Army Medical Research Institute for Infectious Diseases (USAMRIID) and the United States Centers for Disease Control and Prevention (CDC).
I presume we all if ever infected by this virus would ask for the hemopurifier as first treatment. If the hemopurifier is not used on the current "Partners in Health" volunteer admitted at the National Institutes of Health Clinical Center in Bethesda it would approach a situation of legal liability for the doctors and hospital of the NIH if the person dies.
Aethlon disclosed on Nov 19, 2014 "Based on FDA guidance, Aethlon will now provide Hemopurifier® therapy to treat Ebola infection through expanded access "emergency use" provisions in the United States. Expanded access "emergency use" of an investigational device does not require advance FDA approval for life threatening circumstances for which an alternative therapy is not available."
On November 26 2014, "Aethlon disclosed that four Hemopurifiers have been shipped to the Biocontainment Unit at the Nebraska Medical Center (NMC) in Omaha as a therapeutic option to be stockpiled for Ebola patients that may be treated at the NMC. Aethlon further disclosed that it has provided onsite training to NMC clinical personnel related to the implementation of Hemopurifier® therapy within the dialysis infrastructure already located at the center."
Currently there seems to be more interest in the antivirals and vaccines. Zmapp has been mentioned a couple of times in the press and medical blogs with regards to this current NIH patient. There is clearly a pharma bias pushing these treatments at the expense of the persons life. It's understandable to want to find a convenient and easily administered pill that can be used in mass, I want this too, but this needs to be done ethically and not at the expense of these "guinea pig" first patients when there is a proven treatment in the hemopurifier. The patients treated with the best candidate antiviral has died 50% of the time (this is the best average).
Where dialysis machines are available these patients should be getting as the first line of defense the Aethlon hemopurifier. The antivirals and vaccines can have their day when and if they prove effective and have no side effects (the hemopurifier has no known side effects) -- or perhaps ethically can be used now in places where dialysis machines are not available.
It might be ethical to try the antivirals by themselves in countries where dialysis is not readily available but to test them on patients on US soil without the added security of the hemopurifier is simple negligence.
At this point if the hemopurifier is not used it will be medical malpractice in my opinion. The hemopurifier has been given the only FDA "emergency use" approval for Ebola. None of the antivirals or vaccines have to this date been given an equivalent designation. That includes the antivirals Zmapp, Favipiravir, Brincidofovir and TKM-Ebola and all of the vaccines to date.
AEMD’s Hemopurifier device provides a best-in-practice leg up to anyone fighting that dreaded virus, it also provides a leg up in fighting potentially dozens of other more commonplace diseases-those which affect tens of millions of patients the world over if given the chance. Unfortunately these chances need to be wrestled from the hands of the pharma zeitgeist and the attendant narrow sightedness and complacency of many medical professionals.
Although it's not happening at nearly the speed that it should, I'm still optimistic that common sense (based on study results and hard data) will prevail making the hemopurifier the standard of care for many of these most dreaded viral infections.
AI
